ERBB2 and hydrops fetalis: A meta-analysis of 10 randomized clinical trials involving 12,000 patients treated by trastuzumab, a monoclonal antibody targeting HER2 (the family member of EGFR), indicated that the incidence of asymptomatic decline of left ventricular ejection fraction (LVEF, normal range 50–70%) and symptomatic HF was 7.5 and 1.9%, respectively (119).